Precision Medicine Division Using AI, Big Data and Predictive Technologies Launched
Learn More
NovAccess Global to Present at World Orphan Drug Congress
Learn More
NovAccess Leaders Presented at 2023 SBMT Conference
Learn More
FDA Approves Orphan Drug Designation for TLR-AD1
Learn More
Recent Uplist to OTCQB
Learn More
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
Discovery to Science-Led Public Company
Learn More
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
The Journey from Discovery to IPO
Learn More
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
FDA Approves Orphan Drug Designation
Recent Uplist to OTCQB
Recent Uplist to OTCQB
Learn More
Board of Directors Expanded
Patented Immunotherapy Candidate
The Journey from Discovery to IPO
The Journey from Discovery to IPO
Learn More

Our patented approach, TLR-AD1 seeks to bolster the body’s immune system through cellular training; strengthening the body’s defense against cancer.

With TLR-AD1, we will provide Novel Access to the Global market.

Learn About TLR-AD1

Join Us

Submit